A Phase 1, Single Ascending Dose Administration of MIB-725 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Community Dwelling Healthy Adults
Latest Information Update: 27 Feb 2025
At a glance
- Drugs MIB 725 (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions
- Sponsors Metro International Biotech
Most Recent Events
- 20 Feb 2025 Status changed from not yet recruiting to recruiting.
- 19 Feb 2025 New trial record